Radioiodine scintigraphy influences staging and treatment in patients with differentiated thyroid carcinoma. The limit of detection for fractional uptake in an iodine avid focus in a scintigraphic image was determined from the number of lesion net counts and the count density of the tissue background. The count statistics were used to calculate the diagnostic activity required to elevate the si...

introduction: the gastrin releasing peptide (grp) receptor is over expressed in a variety of common human tumors. radiolabeled bombesin analogues have exhibited high binding affinity for these receptors. the aim of this study was to assess the value of a new 99mtc-bombesin analog in the differentiation of malignant from benign breast tumors. methods: 99mtc-bombesin scans were performed in 21 pa...

the method of choice based on several reports [3–5] demonstrating equal efficacy of rhTSH compared to THW. rhTSH-assisted RAI ablative therapy is associated with similar rates of persistent disease and clinical recurrences than those observed after traditional THW preparation, at least in the short-term follow-up [6, 7] . In addition, preparation with either rhTSH or THW appears to have similar...

A 73-y-old patient who had thyroid carcinoma had a post-treatment, whole-body 131I scan. The scan demonstrated an artifact caused by a bracelet contaminated with radioactive perspiration. This finding resulted in an artifact on the scan and had potential radiation safety implications.

Serum thyroglobulin (Tg) measurements in patients with treated differentiated thyroid cancer are usually well correlated with the presence or absence of residual or metastatic thyroid tissue. However, it is not rare to find a patient with detectable serum Tg levels but negative 131I whole-body scan (WBS) and no evidence of disease activity. To clarify the reason for this discrepancy, we decided...

We evaluated the efficacy of recombinant human thyroid-stimulating hormone (rhTSH) versus thyroid hormone withdrawal (THW) prior to radioiodine remnant ablation (RRA) in thyroid cancer. A systematic search of MEDLINE, EMBASE, the Cochrane Library, and SCOPUS was performed. Randomized controlled trials that compared ablation success between rhTSH and THW at 6 to 12 months following RRA were incl...

Radioiodine (I-131) therapy is of proven efficacy for treatment of differentiated thyroid carcinoma (DTC). However, loss of differentiation in recurrent or metastatic DTC which decrease I-131 uptake may decrease the efficacy of I-131 therapy. Therefore, strategies to improve I-131 uptake are mandatory. This study is an open label clinical study to evaluate the effectiveness of 13-cis retinoic a...

BACKGROUND A diagnostic whole-body scan (WBS) is recommended 6 to 12 months after total thyroidectomy and radioactive iodide ablation in intermediate- or high-risk patients with differentiated thyroid cancer (DTC). The aim of this study was to evaluate the necessity of a diagnostic WBS after radioactive iodide ablation in intermediate-risk patients with DTC. METHODS A total of 438 subjects we...